Novo's Next Shot at Dominance: High-Dose Wegovy Takes Aim at Lilly's Zepbound

Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...

Lilly Cuts Low-Dose Zepbound Price Up to 20% for Cash-Pay Buyers

Eli Lilly & Co. is cutting the price for introductory doses of its weight-loss drug Zepbound again, as competition heats up ...
BioSpace

Lilly Cuts Zepbound Prices, Again, When Buying Through DTC Program

Following Novo Nordisk’s price cuts for its own GLP-1 medicines, Eli Lilly is offering discounts for the obesity drug ...
ABC Columbia

Eli Lily cuts price for Zepbound

Monday, Dec. 1, Eli Lilly announced Zepbound will cost less for those who buy the medication straight from the drugmaker.
NBC 6 South Florida

Eli Lilly's Zepbound causes greater weight loss than Novo Nordisk's Wegovy in head-to-head trial

The findings suggest Zepbound may be a superior treatment for weight loss, helping obese or overweight patients lose 20.2% of their body weight, or roughly 50 pounds, on average after 72 weeks in ...
Fierce Pharma

Lilly joins Novo in GLP-1 self-pay price cuts, lowering costs of single-dose Zepbound vials

In the early November announcement of its agreement with the government, Lilly pledged to reduce the self-pay price of ...

Why Novo Nordisk Stock Topped the Market on Thursday

A proposed new federal law could provide some competitive guardrails for the company's most important product.